Kathy Wike, CNM | |
130 Forest Service Dr, Mitchell County Health Department, Bakersville, NC 28705-7047 | |
(828) 688-2371 | |
Not Available |
Full Name | Kathy Wike |
---|---|
Gender | Female |
Speciality | Advanced Practice Midwife |
Location | 130 Forest Service Dr, Bakersville, North Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1992928576 | NPI | - | NPPES |
029 | Other | NC | STATE LICENSE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367A00000X | Advanced Practice Midwife | 029 (North Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kathy Wike, CNM Po Box 251, Montezuma, NC 28653-0251 Ph: (828) 733-5574 | Kathy Wike, CNM 130 Forest Service Dr, Mitchell County Health Department, Bakersville, NC 28705-7047 Ph: (828) 688-2371 |
News Archive
Acurian, Inc., a leading, full-service provider of patient recruitment and retention solutions, announced today at the Patient Recruitment & Retention for Diabetes & Obesity Studies Conference in Amsterdam that it recently completed its enrollment contribution of over 600 diabetes patients for a global, nine-protocol diabetes study.
"Traction was introduced before it was properly evaluated in high-quality randomized trials, and as an intervention is already part of usual practice," said lead author Judy M.A. Clarke, M.D. "It is hard to convince health care providers not to use it."
Advancing healthcare quality to help improve patient outcomes and economic efficiency continues to be a primary focus in 2010 for Elsevier, the leading publisher of scientific, technical and medical information. During HIMSS 2010 (Atlanta, GA, March 1-3), Elsevier Clinical Decision Support will feature solutions that directly impact the quality of care, including evidence-based clinical content and tools; interdisciplinary documentation, planning and guidelines; drug decision support; interactive skills and procedures; data mining and outcomes analysis; and eLearning.
Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.
› Verified 4 days ago